Peptinovo Biopharma Revenue and Competitors

Chemotherapy is the cornerstone of cancer treatment, but its effectiveness is often limited by severe side effects, such as nerve damage or reduced white blood cell counts. These and other debilitating side effects can force dose reductions or treatment discontinuations, impacting a patient's chances of survival.\n\nPeptinovo Biopharma, Inc. has developed a patented drug-delivery platform called PALM™ (US #10,532,105), which is designed to specifically target cancer cells while protecting healthy tissues. Peptinovo aims to improve the effectiveness of proven chemotherapy drugs while significantly minimizing, and potentially eliminating, harmful side effects to the patient.\n\nCancer cells rely on specific nutrient pathways to absorb cholesterol, which fuels their rapid growth. The PALM™ platform mimics a cholesterol carrier (HDL), and like a \Trojan horse,” it delivers chemotherapy drugs directly into cancer cells by disguising them as nutrients. \n\nOur lead drug candidate is PALM™ + Paclitaxel, a first-line therapeutic used for over 30 years to treat many cancers such as breast, ovarian, lung, prostate, and pancreatic. Extensive animal trials demonstrate that PALM + chemotherapy significantly reduces, and often eliminates, the harmful side effects from the chemotherapy. \n\nPeptinovo’s smart drug delivery platform could unleash chemotherapy’s full potential - with the aim to be effective and safer for patients worldwide.